Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - BRAF
 More »

  • Companion Diagnostics: Improving Development Success and Patient...
    Tafinlar® (dabrafenib), a BRAF inhibitor that targets a certain mutation in the BRAF gene, together with a companion diagnostic identifying patients having that specific mutation. ...
    8-5-2013
  • Ovarian Cancer Treatment Milestone Earns Array BioPharma $5M
    Novartis recently detailed plans to initiate Phase III trials of MEK162 in both NRAS- and BRAF-mutant melanoma. All three trials will be conducted as part of the Novartis/Array ...
    7-2-2013
  • Assay Development Driving Personalized Medicine
    ... Merck. "The most notable success stories recently are the identification of BRAF mutations in melanoma for vemurafenib and the identification of ALK translocations for crizotinib." ...
    7-1-2013
  • GSK Hits Trifecta with Melanoma Drug, Dx Approvals
    or unresectable melanoma in adult patients with the BRAF V600E mutation, which accounts for about 85% of all BRAF V600 mutations in metastatic melanoma, according to a study ...
    5-30-2013
  • Companion Diagnostics: 52 Pick-Up
    ... COBAS 4800 BRAF V600 Mutation Test Sponsor/Developer: Roche Molecular Systems Intended Use/Indications for Use: Intended for the qualitative detection of the BRAF V600E mutation in ...
    5-9-2013
  • NGS Sample Prep Library Kit
    Swift Biosciences opened its doors in February 2010 and launched the first retail product in its myT(tm) Primers platform-myT(tm) BRAF-for detection of BRAF mutations in February ...
    4-15-2013
  • Development and Evolution of PCR
    ... In some cases, the assay is co-developed with the drug and is known as a companion diagnostic (e.g., Zelboraf, which targets melanoma tumors harboring the BRAF V600E mutation). The ...
    4-1-2013
  • Advertorial: Swift Biosciences
    ... Swift has developed myT Primers for the common mutations in BRAF and KRAS genes to ... In 2012, Swift launched two Research Use Only (RUO) myT Primer sets for BRAF V600E/K ...
    4-1-2013
  • Personalized Medicine: Translation of Concepts
    Examples include Her-2/neu (Trastuzumab/Lapatinib), KRAS (Cetuximab/Panitumomab), BRAF (Vemurafenib), and CCR5 (Maraviroc). We Lack Model Systems to Predict Drug Response In our ...
    3-19-2013
  • Unlocking Biomarkers' Full Potential
    ... For example, EGFR measures the level of receptor expression; Braf and Kras markers measure the presence of the mutation and translocation in the ALK gene measures gene knockout. It ...
    2-1-2013
  • Tumor Bank Lends Expertise to Drug Firms
    ... Among the newest is a clinically validated BRAF test that detects the V600E mutation found ... The FDA has approved drugs that target BRAF mutations, such as Roche's recently released ...
    2-1-2013
  • A "Very Good Year" for Roche
    Zelboraf® for BRAF V600 mutation-positive metastatic melanoma rang up its first sales in ... Europe and the United States as a result of higher-than-expected BRAF testing rates. ...
    1-30-2013
  • The New Economics of Orphan Diseases
    ... a growing number of orphan indications that are actually sub-populations of larger nonrare diseases, such as BRAF mutated melanoma and ALK-translocated NSCLC," Dr. Meekings says. ...
    1-1-2013
  • Improving Molecular Genetic Testing
    Building a New Standard Figure 1. Reference materials are available from Horizon Diagnostics in gDNA and FFPE formats. Key mutations are shown for EGFR, KRAS, PI3K, and BRAF. Other ...
    12-1-2012
  • Designing Assays to Fit the Application
    ... When Roche developed the cobas 4800 BRAF V600 mutation test as a companion diagnostic to ... hand, was able to detect down to about 5% of cells carrying the mutated BRAF gene. Dr. ...
    11-1-2012
  • More »

    Journal Articles

  • Concomitant BRAFV600E mutation and RET/PTC rearrangement is a...
    Anna Guerra, Pio Zeppa, Maurizio Bifulco, Mario Vitale
    Thyroid
    MAPK cascade, while others suggest that BRAF mutations and RET rearrangements can ... Methods The percentage of mutant BRAF alleles and the presence of RET/PTC rearrangements ...
  • Upregulation of Endocrine Gland-Derived Vascular Endothelial...
    Daniela Pasquali, Angela Santoro, Pantaleo Bufo, Giovanni Conzo, William J Deery, Andrea Renzullo, Giacomo Accardo, Valentina Sacco, Antonio Bellastella, Giuseppe Pannone
    Thyroid
    Patterns, Lymph Node Metastases, and BRAF Mutation Thyroid Background: Endocrine ... The oncogene BRAF V600E mutation is associated with poor clinical outcome of papillary ...
  • Aberrant Promoter Methylation in Overexpression of CITED1 in...
    Miho Sassa, Yoshitaka Hayashi, Reiko Watanabe, Toyone Kikumori, Tsuneo Imai, Junichi Kurebayashi, Tetsuya Kiuchi, Yoshiharu Murata
    Thyroid
    study suggested a positive association of BRAF mutation with CITED1 overexpression. ... normal tissues from 19 patients. The BRAF mutation status of the cells and clinical ...
  • Molecular Alterations in Partially-Encapsulated/Well-Circumscribed...
    Brooke E Howitt, Yonghui Jia, Lynette M. Sholl, Justine Barletta
    Thyroid
    mutations but not BRAF mutations. In contrast, infiltrative tumors have significant metastatic potential, a risk of recurrence, and a BRAF mutation frequency of approximately 25%. ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Top Paid Women in Biopharma

Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Suggest a Poll